The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.

This is an open-label study to evaluate the safety and efficacy of N-acetyl-L-cysteine in patients with Chronic neuropathic pain.

Inclusion Criteria:

• 18-65 years old
• non-cancer neuropathic pain
• stable dose of opioids for pain
• using breakthrough pain meds
• still with persistent pain per VAS

Exclusion Criteria:

• pregnant or nursing
• serious medical or psychiatric illness (including uncontrolled hypertension)
• active stomach ulcer, history or seizures or asthma
• breakthrough pain meds other than opioids
• using illicit drugs